Ameriprise
ZLAB icon

Ameriprise’s Zai Lab ZLAB Stock Holding History

Ameriprise’s Portfolio ZLAB Stock Details ZLAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.58M Buy
243,557
+62,424
+34% +$1.16M ﹤0.01% 2490
2025
Q4 		$3.2M Buy
+181,133
New +$4.24M ﹤0.01% 2747
2024
Q1 		– Sell
-18,056
Closed -$493K – 3968
2023
Q4 		$493K Buy
18,056
+1,109
+7% +$29.3K ﹤0.01% 3450
2023
Q3 		$412K Sell
16,947
-1,255
-7% -$33.4K ﹤0.01% 3482
2023
Q2 		$505K Sell
18,202
-2,438
-12% -$79.7K ﹤0.01% 3436
2023
Q1 		$686K Buy
20,640
+3,539
+21% +$136K ﹤0.01% 3309
2022
Q4 		$525K Sell
17,101
-6,699
-28% -$211K ﹤0.01% 3391
2022
Q3 		$814K Sell
23,800
-8,781
-27% -$376K ﹤0.01% 3207
2022
Q2 		$1.13M Sell
32,581
-663
-2% -$23.4K ﹤0.01% 3069
2022
Q1 		$1.46M Sell
33,244
-537,146
-94% -$26M ﹤0.01% 3050
2021
Q4 		$35.8M Buy
570,390
+173,023
+44% +$14.7M 0.01% 1004
2021
Q3 		$41.9M Buy
397,367
+108,442
+38% +$15.6M 0.01% 852
2021
Q2 		$51.1M Buy
288,925
+33,215
+13% +$5.34M 0.02% 794
2021
Q1 		$34.1M Buy
255,710
+232,753
+1,014% +$36M 0.01% 965
2020
Q4 		$3.11M Sell
22,957
-7,575
-25% -$771K ﹤0.01% 2572
2020
Q3 		$2.54M Buy
30,532
+69
+0.2% +$5.54K ﹤0.01% 2525
2020
Q2 		$2.5M Sell
30,463
-621
-2% -$42K ﹤0.01% 2491
2020
Q1 		$1.6M Sell
31,084
-5,153
-14% -$269K ﹤0.01% 2588
2019
Q4 		$1.51M Buy
36,237
+1,147
+3% +$42.3K ﹤0.01% 2873
2019
Q3 		$1.14M Sell
35,090
-7,297
-17% -$250K ﹤0.01% 2974
2019
Q2 		$1.48M Buy
42,387
+45
+0.1% +$1.32K ﹤0.01% 2904
2019
Q1 		$1.25M Sell
42,342
-17,154
-29% -$470K ﹤0.01% 2950
2018
Q4 		$1.38M Sell
59,496
-6,255
-10% -$116K ﹤0.01% 2799
2018
Q3 		$1.28M Sell
65,751
-35,074
-35% -$761K ﹤0.01% 2980
2018
Q2 		$2.34M Buy
100,825
+270
+0.3% +$5.82K ﹤0.01% 2673
2018
Q1 		$2.15M Buy
100,555
+555
+0.6% +$12.6K ﹤0.01% 2666
2017
Q4 		$2.12M Hold
100,000
– – ﹤0.01% 2629
2017
Q3 		$2.7M Buy
+100,000
New +$2.79M ﹤0.01% 2452

Other funds holding ZLAB

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Ameriprise's ZLAB Position: Q1 2026 in Review

Ameriprise increased its Zai Lab (ZLAB) stake by 34% in Q1 2026, buying an estimated $1.16M and bringing the position to 243,557 shares worth $4.58M. The position accounts for ﹤0.01% of the portfolio, ranked #2490.

Ameriprise first reported a position in ZLAB in Q3 2017 and has held it in 28 quarters since. The position peaked at $51.1M in Q2 2021. 99 funds tracked by Wall St. Rank hold ZLAB as of Q1 2026.

  • Ameriprise held 243,557 shares of Zai Lab worth $4.58M as of Q1 2026.
  • Ameriprise bought 62,424 Zai Lab shares in Q1 2026, an estimated $1.16M.
  • Zai Lab made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2490 holding.
  • Ameriprise first reported a position in Zai Lab in Q3 2017 and has held it in 28 quarters since.
  • Ameriprise's Zai Lab position peaked at $51.1M in Q2 2021.
  • 99 funds tracked by Wall St. Rank held Zai Lab as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.